# OnCo record nct07001618 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07001618/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07001618", "NCT07001618" ;
  schema:name "Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot"@en ;
  schema:alternateName "IMMUNOLIFE2"@en ;
  schema:description "A phase 2 trial of cemiplimab, cisplatin, pemetrexed, bevacizumab and other drugs in lung cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07001618/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07001618> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/maat-pharma/>, <https://onco.cc/companies/regeneron/> .